FR2181734A1 - - Google Patents

Info

Publication number
FR2181734A1
FR2181734A1 FR7305303A FR7305303A FR2181734A1 FR 2181734 A1 FR2181734 A1 FR 2181734A1 FR 7305303 A FR7305303 A FR 7305303A FR 7305303 A FR7305303 A FR 7305303A FR 2181734 A1 FR2181734 A1 FR 2181734A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7305303A
Other versions
FR2181734B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH229972A external-priority patent/CH574247A5/de
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of FR2181734A1 publication Critical patent/FR2181734A1/fr
Application granted granted Critical
Publication of FR2181734B1 publication Critical patent/FR2181734B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
FR7305303A 1972-02-17 1973-02-15 Expired FR2181734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229972A CH574247A5 (en) 1972-02-17 1972-02-17 Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
CH1782972 1972-12-07

Publications (2)

Publication Number Publication Date
FR2181734A1 true FR2181734A1 (fr) 1973-12-07
FR2181734B1 FR2181734B1 (fr) 1975-10-10

Family

ID=25690055

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7305303A Expired FR2181734B1 (fr) 1972-02-17 1973-02-15

Country Status (18)

Country Link
US (1) US3869549A (fr)
JP (1) JPS4892516A (fr)
AR (1) AR197116A1 (fr)
AT (1) AT335615B (fr)
AU (1) AU472655B2 (fr)
BE (1) BE795516A (fr)
CS (1) CS172967B2 (fr)
DD (1) DD102584A5 (fr)
DE (1) DE2306075A1 (fr)
DK (1) DK134098B (fr)
ES (1) ES411655A1 (fr)
FR (1) FR2181734B1 (fr)
GB (1) GB1418408A (fr)
IE (1) IE37151B1 (fr)
IL (1) IL41416A (fr)
NL (1) NL7300953A (fr)
PL (1) PL90318B1 (fr)
SE (1) SE7600435L (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235914A1 (fr) * 1973-07-02 1975-01-31 Takeda Chemical Industries Ltd

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254043C2 (de) * 1972-11-04 1985-01-24 Hoechst Ag, 6230 Frankfurt LH-Releasing Hormon zur nasalen Applikation
DE2254061A1 (de) * 1972-11-04 1974-05-16 Hoechst Ag Lh-releasing hormon zur nasalen applikation
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
ES8702440A1 (es) * 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
DE3502099A1 (de) * 1985-01-23 1986-08-07 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
US4804742A (en) * 1985-06-06 1989-02-14 Rorer Pharmaceutical Corporation Amide analogs of calcitonin
US4650854A (en) * 1985-06-06 1987-03-17 Usv Pharmaceutical Corporation Amide analogs of calcitonin
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
ZA866218B (en) * 1985-08-23 1988-03-30 Lilly Co Eli Injectable sustained release formulation
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
KR19990071255A (ko) 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2563533C (fr) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
EP2049081B1 (fr) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Systemes d'administration osmotiques et ensembles pistons
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2691531C (fr) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation de particules de peptide ou de proteine submicroniques stables par congelation de film mince
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
HUE033611T2 (en) * 2008-09-17 2017-12-28 Chiasma Inc Pharmaceutical preparations and associated dosing procedures
CA2743789C (fr) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Suspensions hautement concentrees de faible viscosite
JP5718925B2 (ja) 2009-09-28 2015-05-13 インターシア セラピューティクス，インコーポレイティド 実質的な定常状態薬物送達の迅速な確立及び／又は停止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016126830A1 (fr) 2015-02-03 2016-08-11 Chiasma Inc. Méthode de traitement de maladies
WO2016196851A2 (fr) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Systèmes de mise en place et de retrait d'implant
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
WO2017200943A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides sélectifs du récepteur du glucagon et méthodes pour les employer
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944940A (en) * 1956-01-16 1960-07-12 Armour & Co Adrenocorticotrophin and zinc composition
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235914A1 (fr) * 1973-07-02 1975-01-31 Takeda Chemical Industries Ltd

Also Published As

Publication number Publication date
GB1418408A (en) 1975-12-17
DE2306075A1 (de) 1973-08-23
ATA140873A (de) 1976-07-15
ES411655A1 (es) 1976-09-01
AU5218973A (en) 1974-08-15
JPS4892516A (fr) 1973-11-30
DK134098B (da) 1976-09-13
AT335615B (de) 1977-03-25
IL41416A0 (en) 1973-03-30
DD102584A5 (fr) 1973-12-20
IL41416A (en) 1976-03-31
US3869549A (en) 1975-03-04
IE37151B1 (en) 1977-05-11
SE7600435L (sv) 1976-01-16
AR197116A1 (es) 1974-03-15
FR2181734B1 (fr) 1975-10-10
PL90318B1 (fr) 1977-01-31
NL7300953A (fr) 1973-08-21
AU472655B2 (en) 1976-06-03
DK134098C (fr) 1977-02-21
IE37151L (en) 1973-08-17
CS172967B2 (fr) 1977-01-28
BE795516A (fr) 1973-08-16

Similar Documents

Publication Publication Date Title
CS150082B1 (fr)
CH588414A5 (fr)
CH567548A5 (fr)
BG18206A1 (fr)
BG18305A1 (fr)
BG18348A1 (fr)
BG19329A1 (fr)
BG19581A3 (fr)
BG19803A3 (fr)
BG20098A3 (fr)
BG20249A1 (fr)
BG20403A3 (fr)
BG22338A1 (fr)
BG26486A1 (fr)
CH258773A4 (fr)
CH559799B5 (fr)
CH559878A5 (fr)
CH561123A5 (fr)
CH561308A5 (fr)
CH561317A (fr)
CH563077A5 (fr)
CH564060A5 (fr)
CH565340A5 (fr)
CH566548A5 (fr)
CH566666A5 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse